Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T24555
(Former ID: TTDI02256)
|
|||||
| Target Name |
ADRB2 messenger RNA (ADRB2 mRNA)
|
|||||
| Synonyms |
Beta-2 adrenoreceptor (mRNA); Beta-2 adrenoceptor (mRNA); Beta-2 adrenergic receptor (mRNA); B2AR (mRNA); ADRB2R (mRNA)
Click to Show/Hide
|
|||||
| Gene Name |
ADRB2
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Glaucoma [ICD-11: 9C61] | |||||
| Function |
The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine. Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins.
Click to Show/Hide
|
|||||
| BioChemical Class |
mRNA target
|
|||||
| UniProt ID | ||||||
| Sequence |
MGQPGNGSAFLLAPNGSHAPDHDVTQERDEVWVVGMGIVMSLIVLAIVFGNVLVITAIAK
FERLQTVTNYFITSLACADLVMGLAVVPFGAAHILMKMWTFGNFWCEFWTSIDVLCVTAS IETLCVIAVDRYFAITSPFKYQSLLTKNKARVIILMVWIVSGLTSFLPIQMHWYRATHQE AINCYANETCCDFFTNQAYAIASSIVSFYVPLVIMVFVYSRVFQEAKRQLQKIDKSEGRF HVQNLSQVEQDGRTGHGLRRSSKFCLKEHKALKTLGIIMGTFTLCWLPFFIVNIVHVIQD NLIRKEVYILLNWIGYVNSGFNPLIYCRSPDFRIAFQELLCLRRSSLKAYGNGYSSNGNT GEQSGYHVEQEKENKLLCEDLPGTEDFVGHQGTVPSDNIDSQGRNCSTNDSLL Click to Show/Hide
|
|||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 2 Clinical Trial Drugs | + | ||||
| 1 | Bamosiran | Drug Info | Phase 2 | Glaucoma/ocular hypertension | [2] | |
| 2 | SYL-040012 | Drug Info | Phase 2 | Ocular hypertension | [3] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Inhibitor | [+] 1 Inhibitor drugs | + | ||||
| 1 | Bamosiran | Drug Info | [4] | |||
| Cell-based Target Expression Variations | Top | |||||
|---|---|---|---|---|---|---|
| Cell-based Target Expression Variations | ||||||
| Target Profiles in Patients | Top | |||||
|---|---|---|---|---|---|---|
| Target Expression Profile (TEP) | ||||||
| Target Affiliated Biological Pathways | Top | |||||
|---|---|---|---|---|---|---|
| KEGG Pathway | [+] 7 KEGG Pathways | + | ||||
| 1 | Calcium signaling pathway | |||||
| 2 | cGMP-PKG signaling pathway | |||||
| 3 | cAMP signaling pathway | |||||
| 4 | Neuroactive ligand-receptor interaction | |||||
| 5 | Endocytosis | |||||
| 6 | Adrenergic signaling in cardiomyocytes | |||||
| 7 | Salivary secretion | |||||
| NetPath Pathway | [+] 1 NetPath Pathways | + | ||||
| 1 | TCR Signaling Pathway | |||||
| Panther Pathway | [+] 2 Panther Pathways | + | ||||
| 1 | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| 2 | Beta2 adrenergic receptor signaling pathway | |||||
| PID Pathway | [+] 2 PID Pathways | + | ||||
| 1 | Arf6 trafficking events | |||||
| 2 | Arf6 signaling events | |||||
| Reactome | [+] 2 Reactome Pathways | + | ||||
| 1 | Adrenoceptors | |||||
| 2 | G alpha (s) signalling events | |||||
| WikiPathways | [+] 6 WikiPathways | + | ||||
| 1 | Monoamine GPCRs | |||||
| 2 | Calcium Regulation in the Cardiac Cell | |||||
| 3 | GPCRs, Class A Rhodopsin-like | |||||
| 4 | GPCR ligand binding | |||||
| 5 | GPCR downstream signaling | |||||
| 6 | GPCRs, Other | |||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. Mol Ther. 2014 Jan;22(1):81-91. | |||||
| REF 2 | ClinicalTrials.gov (NCT02250612) SYL040012, Treatment for Open Angle Glaucoma (SYLTAG). U.S. National Institutes of Health. | |||||
| REF 3 | ClinicalTrials.gov (NCT02250612) SYL040012, Treatment for Open Angle Glaucoma. U.S. National Institutes of Health. | |||||
| REF 4 | Clinical pipeline report, company report or official report of Sylentis. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.